SOCRA Adverse Event Safety Reporting 2

Question 1

According to FDA regulations (21 CFR 312.32), which of the following outcomes makes an adverse event classified as 'serious'?

Accepted Answer

Results in persistent or significant disability or incapacity

Answer

Causes mild nausea lasting more than 24 hours

Answer

Requires an unscheduled outpatient clinic visit

Answer

Causes temporary fatigue or lethargy

Question 2

An investigator must report a serious adverse event (SAE) to the sponsor within what timeframe per ICH E6 GCP guidelines?

Accepted Answer

Within 24 hours of awareness

Answer

Immediately upon occurrence

Answer

Within 7 calendar days of awareness

Answer

Within 15 calendar days of occurrence

Question 3

Which FDA form is used by sponsors to submit expedited IND safety reports (individual case safety reports) to the agency?

Accepted Answer

FDA Form 3500A (MedWatch)

Answer

FDA Form 1572 (Statement of Investigator)

Answer

FDA Form 356h (NDA Application)

Answer

FDA Form 2253 (Promotional Materials)

Question 4

In the context of adverse event reporting, an event is considered 'unexpected' when:

Accepted Answer

Its nature, severity, or frequency is not consistent with the Investigator's Brochure

Answer

It occurs in less than 1% of clinical trial subjects

Answer

It has never been described in the published scientific literature

Answer

It occurs without a clear temporal relationship to drug administration

Question 5

A sponsor must report a fatal or life-threatening unexpected suspected adverse reaction (SUSAR) to the FDA within:

Accepted Answer

7 calendar days

Answer

15 calendar days

Answer

24 hours

Answer

30 calendar days

Question 6

Which element is required to classify an adverse event as a 'suspected adverse reaction' rather than a general AE?

Accepted Answer

There is a reasonable possibility that the investigational drug caused the event

Answer

The event results in hospitalization

Answer

The event is observed in more than one subject

Answer

The event is listed in the protocol as a safety endpoint

Question 7

Under 21 CFR 312.32, non-fatal, non-life-threatening unexpected SUSARs must be reported to the FDA within:

Accepted Answer

15 calendar days

Answer

7 calendar days

Answer

30 calendar days

Answer

60 calendar days